CCO Independent Conference Coverage of the 2022 ESMO Annual Meeting *

September 9-13, 2022; Paris, France
Review experts’ conference preview commentary, Capsule Summary slidesets, and an expert analysis of key studies from the 2022 ESMO Annual Congress.

Share

Program Content

ESMO 2022 Highlights
Key Studies in Breast, Gynecologic, Renal Cell, Urothelial, Lung, Hepatobiliary, and Skin Cancers: CCO Independent Conference Highlights of the 2022 ESMO Congress
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: November 14, 2022

Expires: November 13, 2023

View Activity
ADAURA Update
ADAURA Trial Update: Adjuvant Osimertinib vs Placebo After Complete Resection in Stage IB-IIIA EGFR-Mutated NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 19, 2022

Expires: September 18, 2023

View Activity
SOLO-1: 7-Yr OS
SOLO-1: OS With 7-Yr Follow-up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation Who Received Maintenance Olaparib
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 15, 2022

Expires: September 14, 2023

View Activity
COSMIC-313
COSMIC-313: Phase III Study of Nivolumab + Ipilimumab ± Cabozantinib in Previously Untreated IMDC Intermediate- or Poor-Risk Advanced RCC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 22, 2022

Expires: September 21, 2023

View Activity
CheckMate 274: Biomarker Analysis
CheckMate 274: Exploratory Analysis of DFS According to Select Biomarkers in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma Receiving Adjuvant Nivolumab
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 22, 2022

Expires: September 21, 2023

View Activity
RELATIVITY-047: Response Results
Phase II/III RELATIVITY-047: Additional Response Results With Nivolumab ± Relatlimab in Previously Untreated Metastatic or Unresectable Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 19, 2022

Expires: September 18, 2023

View Activity
MONARCH 3: OS Update
MONARCH 3 Interim OS: Abemaciclib + Nonsteroidal AI as First-line Treatment for HR+/HER2- Advanced Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 13, 2022

Expires: September 12, 2023

View Activity
TROPiCS-02: OS Update
TROPiCS-02: OS With Sacituzumab Govitecan vs Treatment of Physician’s Choice for HR+/HER2- Advanced Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 13, 2022

Expires: September 12, 2023

View Activity
Phase II BELLINI
BELLINI Phase II Trial: Nivolumab + Ipilimumab in Patients With Early-Stage TNBC With Tumor-Infiltrating Lymphocytes
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 12, 2022

Expires: September 11, 2023

View Activity
ReFocus
ReFocus Phase I/II Trial of RLY-4008 in Patients With FGFR Inhibitor–Naive Cholangiocarcinoma With FGFR2 Alteration
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 22, 2022

Expires: September 21, 2023

View Activity
LEAP-002: Primary Results
LEAP-002: Placebo-Controlled Phase III Trial of Lenvatinib ± Pembrolizumab as First-line Therapy for Advanced HCC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 19, 2022

Expires: September 18, 2023

View Activity
EV-103 Cohort K
EV-103 Cohort K: Enfortumab Vedotin ± Pembrolizumab in Untreated Cisplatin-Ineligible Patients With Locally Advanced/Metastatic Urothelial Carcinoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 22, 2022

Expires: September 21, 2023

View Activity
CheckMate 915 ctDNA Analyses
Pretreatment ctDNA and Additional Factors Associated With Disease Recurrence in Stage IIIB-D/IV Melanoma Treated With Adjuvant Immunotherapy in CheckMate 915
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 23, 2022

Expires: September 22, 2023

View Activity
CodeBreaK 200
CodeBreaK 200 Phase III Trial: Sotorasib vs Docetaxel for Patients With Previously Treated Advanced NSCLC With KRAS G12C Mutation
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 22, 2022

Expires: September 21, 2023

View Activity
PAOLA-1 Final OS
PAOLA-1 Phase III Trial: Final Overall Survival Results of Maintenance Olaparib + Bevacizumab in Patients With Newly Diagnosed Advanced Ovarian Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 27, 2022

Expires: September 26, 2023

View Activity
CheckMate 816 Efficacy by Features
CheckMate 816: Association of Pathologic Features With Efficacy Outcomes for Neoadjuvant Nivolumab + Platinum-Doublet CT in Resectable NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 16, 2022

Expires: September 15, 2023

View Activity
DESTINY-Lung02: Interim Analyses
DESTINY-Lung02: Interim Results With Trastuzumab Deruxtecan (T-DXd) in Patients With Previously Treated HER2-Mutated Metastatic NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 26, 2022

Expires: September 25, 2023

View Activity
SWOG S1801
SWOG S1801: Neoadjuvant vs Adjuvant Treatment With Pembrolizumab in Patients With Resectable Stage III-IV Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 23, 2022

Expires: September 22, 2023

View Activity
CheckMate 914: Nivo/Ipi in RCC
CheckMate 914 (Part A): Adjuvant Nivolumab + Ipilimumab vs Placebo in Localized RCC at High Risk of Relapse Following Nephrectomy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 19, 2022

Expires: September 18, 2023

View Activity
ESMO 2022: Preview
An Expert’s Guide to ESMO 2022: A Preview of the Top Abstracts
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: September 08, 2022

Expires: September 07, 2023

View Activity

Faculty

cover img faculity

Nicoletta Colombo, MD

Professor of Obstetrics and Gynecology
University of Milan-Bicocca
European Institute of Oncology
Milan, Italy

cover img faculity

Robert Motzer, MD

Attending Physician
Memorial Sloan-Kettering Cancer Center
New York, New York

cover img faculity

Sapna P. Patel, MD

Chair, SWOG Melanoma Committee
SWOG Cancer Research Network
Associate Professor, Director of the Uveal Melanoma Program
The University of Texas MD Anderson Cancer Center
Houston, Texas

cover img faculity

David Planchard, MD, PhD

David Planchard, MD, PhD                                                                                            Head of Thoracic Group
Department of Medical Oncology
Gustave Roussy
Villejuif, France

cover img faculity

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

cover img faculity

Rachna Shroff, MD, MS

Professor of Medicine
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona

cover img faculity

Sara Tolaney, MD, MPH

Associate Professor of Medicine
Division of Breast Oncology
Harvard Medical School
Chief, Division of Breast Oncology
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bristol Myers Squibb

Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.